Omalizumab in severe asthma: real life study

Conclusions: After 12 months of Omalizumab, patients had symptomatic improvement (reduction of total exacerbations and higher scores in ACT), improvement in lung function (FEV1), reductions of daily mean dose of inhaled corticosteroids and suspension of oral corticosteroids, proving its therapeutic efficacy.

Source: European Respiratory Journal - November 20, 2019 Category: Respiratory Medicine Authors: Costa e Silva, M., Sucena, I., Ladeira, I., Franco, I., Pascoal, I., Carvalho, A., Lima, R. Tags: Airway pharmacology and treatment Source Type: research